Abstract
Radiotherapy is an important component of the treatment for primary and metastatic brain tumors. Due to the close proximity of critical structures and normal brain parenchyma, Central Nervous System (CNS) radiotherapy is associated with adverse effects such as neurocognitive deficits, which must be weighed against the benefit of improved tumor control. Advanced radiotherapy technology may help to mitigate toxicity risks, although there is a paucity of high-level evidence to support its use. Recent advances have been made in the treatment for gliomas, meningiomas, benign tumors, and metastases, although outcomes remain poor for many high grade tumors. This review highlights recent developments in CNS radiotherapy, discusses common treatment toxicities, critically reviews advanced radiotherapy technologies, and highlights promising treatment strategies to improve clinical outcomes in the future.
Keywords: Radiation, radiotherapy, brain tumor, central nervous system, intensity-modulated radiotherapy, proton therapy.
Graphical Abstract
[1]
Ostrom QT, Gittleman H, Fulop J, et al. CBTRUS Statistical Report: Primary brain and central nervous system tumors diagnosed in the United States in 2008-2012. Neuro-oncol 2015; 17(Suppl. 4): iv1-iv62.
[3]
Liu BL, Cheng JX, Zhang X, Zhang W. Controversies concerning the application of brachytherapy in central nervous system tumors. J Cancer Res Clin Oncol 2010; 136(2): 173-85.
[4]
Belka C, Budach W, Kortmann RD, Bamberg M. Radiation induced CNS toxicity--molecular and cellular mechanisms. Br J Cancer 2001; 85(9): 1233-9.
[5]
Werner-Wasik M, Rudoler S, Preston PE, et al. Immediate side effects of stereotactic radiotherapy and radiosurgery. Int J Radiat Oncol Biol Phys 1999; 43(2): 299-304.
[6]
Minniti G, Clarke E, Lanzetta G, et al. Stereotactic radiosurgery for brain metastases: Analysis of outcome and risk of brain radionecrosis. Radiat Oncol 2011; 6: 48.
[7]
Harris JR, Levene MB. Visual complications following irradiation for pituitary adenomas and craniopharyngiomas. Radiology 1976; 120(1): 167-71.
[8]
Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: Initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol 2002; 20(9): 2267-76.
[9]
Scoccianti S, Detti B, Gadda D, et al. Organs at risk in the brain and their dose-constraints in adults and in children: A radiation oncologist’s guide for delineation in everyday practice. Radiother Oncol 2015; 114(2): 230-8.
[10]
West CM, Barnett GC. Genetics and genomics of radiotherapy toxicity: towards prediction. Genome Med 2011; 3(8): 52.
[11]
Klein M, Heimans JJ, Aaronson NK, et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: A comparative study. Lancet 2002; 360(9343): 1361-8.
[12]
Douw L, Klein M, Fagel SS, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: Long-term follow-up. Lancet Neurol 2009; 8(9): 810-8.
[13]
Brown PD, Jaeckle K, Ballman KV, et al. Effect of radiosurgery alone vs. radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: A Randomized Clinical Trial. JAMA 2016; 316(4): 401-9.
[14]
Greene-Schloesser D, Robbins ME, Peiffer AM, Shaw EG, Wheeler KT, Chan MD. Radiation-induced brain injury: A review. Front Oncol 2012; 2: 73.
[15]
Noda SE, Lautenschlaeger T, Siedow MR, et al. Technological advances in radiation oncology for central nervous system tumors. Semin Radiat Oncol 2009; 19(3): 179-86.
[16]
Veldeman L, Madani I, Hulstaert F, et al. Evidence behind use of intensity-modulated radiotherapy: A systematic review of comparative clinical studies. Lancet Oncol 2008; 9(4): 367-75.
[17]
Amelio D, Lorentini S, Schwarz M, Amichetti M. Intensity-modulated radiation therapy in newly diagnosed glioblastoma: A systematic review on clinical and technical issues. Radiother Oncol 2010; 97(3): 361-9.
[18]
Lorentini S, Amelio D, Giri MG, et al. IMRT or 3D-CRT in glioblastoma? A dosimetric criterion for patient selection. Technol Cancer Res Treat 2013; 12(5): 411-20.
[19]
Chan JL, Lee SW, Fraass BA, et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy. J Clin Oncol 2002; 20(6): 1635-42.
[20]
Merchant TE, Conklin HM, Wu S, Lustig RH, Xiong X. Late effects of conformal radiation therapy for pediatric patients with low-grade glioma: Prospective evaluation of cognitive, endocrine, and hearing deficits. J Clin Oncol 2009; 27(22): 3691-7.
[21]
Polkinghorn WR, Dunkel IJ, Souweidane MM, et al. Disease control and ototoxicity using intensity-modulated radiation therapy tumor-bed boost for medulloblastoma. Int J Radiat Oncol Biol Phys 2011; 81(3): e15-20.
[22]
Pirzkall A, Carol M, Lohr F, Höss A, Wannenmacher M, Debus J. Comparison of intensity-modulated radiotherapy with conventional conformal radiotherapy for complex-shaped tumors. Int J Radiat Oncol Biol Phys 2000; 48(5): 1371-80.
[23]
Hermanto U, Frija EK, Lii MJ, Chang EL, Mahajan A, Woo SY. Intensity-modulated radiotherapy (IMRT) and conventional three-dimensional conformal radiotherapy for high-grade gliomas: Does IMRT increase the integral dose to normal brain? Int J Radiat Oncol Biol Phys 2007; 67(4): 1135-44.
[24]
Mailhot Vega RB, Kim J, Bussière M, et al. Cost effectiveness of proton therapy compared with photon therapy in the management of pediatric medulloblastoma. Cancer 2013; 119(24): 4299-307.
[25]
Patel S, Kostaras X, Parliament M, et al. Recommendations for the referral of patients for proton-beam therapy, an Alberta Health Services report: A model for Canada? Curr Oncol 2014; 21(5): 251-62.
[26]
Allen AM, Pawlicki T, Dong L, et al. An evidence based review of proton beam therapy: The report of ASTRO’s emerging technology committee. Radiother Oncol 2012; 103(1): 8-11.
[27]
Armoogum KS, Thorp N. Dosimetric comparison and potential for improved clinical outcomes of paediatric CNS patients treated with protons or IMRT. Cancers (Basel) 2015; 7(2): 706-22.
[28]
Chung CS, Yock TI, Nelson K, Xu Y, Keating NL, Tarbell NJ. Incidence of second malignancies among patients treated with proton versus photon radiation. Int J Radiat Oncol Biol Phys 2013; 87(1): 46-52.
[29]
Yock TI, Bhat S, Szymonifka J, et al. Quality of life outcomes in proton and photon treated pediatric brain tumor survivors. Radiother Oncol 2014; 113(1): 89-94.
[30]
Moeller BJ, Chintagumpala M, Philip JJ, et al. Low early ototoxicity rates for pediatric medulloblastoma patients treated with proton radiotherapy. Radiat Oncol 2011; 6: 58.
[31]
Brown AP, Barney CL, Grosshans DR, et al. Proton beam craniospinal irradiation reduces acute toxicity for adults with medulloblastoma. Int J Radiat Oncol Biol Phys 2013; 86(2): 277-84.
[32]
Merchant TE, Hua CH, Shukla H, Ying X, Nill S, Oelfke U. Proton versus photon radiotherapy for common pediatric brain tumors: comparison of models of dose characteristics and their relationship to cognitive function. Pediatr Blood Cancer 2008; 51(1): 110-7.
[33]
Eckel-Passow JE, Lachance DH, Molinaro AM, et al. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 2015; 372(26): 2499-508.
[34]
Cancer Genome Atlas Research Network Brat DJ, Verhaak RG, etal. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 2015; 372(26): 2481-98.
[35]
Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352(10): 987-96.
[36]
Harasaki Y, Waziri A. Potential usefulness of radiosensitizers in glioblastoma. Neurosurg Clin N Am 2012; 23(3): 429-37.
[37]
Barbarite E, Sick JT, Berchmans E, et al. The role of brachytherapy in the treatment of glioblastoma multiforme. Neurosurg Rev 2017; 40(2): 195-211.
[38]
Biswas T, Okunieff P, Schell MC, et al. Stereotactic radiosurgery for glioblastoma: retrospective analysis. Radiat Oncol 2009; 4: 11.
[39]
Stupp R, Taillibert S, Kanner AA, et al. Maintenance therapy with tumor-treating fields plus temozolomide vs. temozolomide alone for glioblastoma: A Randomized Clinical Trial. JAMA 2015; 314(23): 2535-43.
[40]
Kirson ED, Dbalý V, Tovarys F, et al. Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc Natl Acad Sci USA 2007; 104(24): 10152-7.
[41]
Perry J, Laperriere N, O'Callaghan CJ, et al. A phase III randomized controlled trial of short-course radiotherapy with or without
concomitant and adjuvant temozolomide in elderly patients with
glioblastoma (CCTG CE.6, EORTC 26062-22061, TROG 08.02,
NCT00482677). J Clin Oncol 2016; 34(suppl): abstr LBA2..
[42]
Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: A prospective randomized clinical trial. J Clin Oncol 2004; 22(9): 1583-8.
[43]
Malmström A, Grønberg BH, Marosi C, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: The Nordic randomised, phase 3 trial. Lancet Oncol 2012; 13(9): 916-26.
[44]
Roa W, Kepka L, Kumar N, et al. International atomic energy agency randomized phase iii study of radiation therapy in elderly and/or frail patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 2015; 33(35): 4145-50.
[45]
Reddy K, Damek D, Gaspar LE, et al. Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2012; 84(3): 655-60.
[46]
Wick W, Platten M, Meisner C, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: The NOA-08 randomised, phase 3 trial. Lancet Oncol 2012; 13(7): 707-15.
[47]
Stupp R, Brada M, van den Bent MJ, et al. High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014; 25(Suppl. 3): iii93-101.
[48]
van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: Long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 2013; 31(3): 344-50.
[49]
Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: Long-term results of RTOG 9402. J Clin Oncol 2013; 31(3): 337-43.
[50]
Van Den Bent MJ, Erridge S, Vogelbaum MA, et al. Results of the
interim analysis of the EORTC randomized phase III CATNON
trial on concurrent and adjuvant temozolomide in anaplastic glioma
without 1p/19q co-deletion: An Intergroup trial J Clin Oncol 2016;
34(suppl): abstr LBA2000.
[51]
Wick W, Roth P, Hartmann C, et al. Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. Neuro-oncol 2016.
[http://dx.doi.org/10.1093/neuonc/now133]
[http://dx.doi.org/10.1093/neuonc/now133]
[52]
Buckner JC, Shaw EG, Pugh SL, et al. Radiation plus procarbazine, ccnu, and vincristine in low-grade glioma. N Engl J Med 2016; 374(14): 1344-55.
[53]
van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: The EORTC 22845 randomised trial. Lancet 2005; 366(9490): 985-90.
[54]
Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 2002; 20(8): 2076-84.
[55]
Rogers L, Barani I, Chamberlain M, et al. Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review. J Neurosurg 2015; 122(1): 4-23.
[56]
Minniti G, Amichetti M, Enrici RM. Radiotherapy and radiosurgery for benign skull base meningiomas. Radiat Oncol 2009; 4: 42.
[57]
Brada M, Ajithkumar TV, Minniti G. Radiosurgery for pituitary adenomas. Clin Endocrinol (Oxf) 2004; 61(5): 531-43.
[58]
Minniti G, Saran F, Traish D, et al. Fractionated stereotactic conformal radiotherapy following conservative surgery in the control of craniopharyngiomas. Radiother Oncol 2007; 82(1): 90-5.
[59]
Connell PP, Macdonald RL, Mansur DB, Nicholas MK, Mundt AJ. Tumor size predicts control of benign meningiomas treated with radiotherapy. Neurosurgery 1999; 44(6): 1194-9.
[60]
Maniakas A, Saliba I. Conservative management versus stereotactic radiation for vestibular schwannomas: A meta-analysis of patients with more than 5 years’ follow-up. Otol Neurotol 2012; 33(2): 230-8.
[61]
Brower JV, Amdur RJ, Kirwan J, Mendenhall WM, Friedman W. Radiation therapy for optic nerve sheath meningioma. Pract Radiat Oncol 2013; 3(3): 223-8.
[62]
Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990; 322(8): 494-500.
[63]
Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: Phase III results of the RTOG 9508 randomised trial. Lancet 2004; 363(9422): 1665-72.
[64]
Tsao MN, Rades D, Wirth A, et al. Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): An American Society for Radiation Oncology evidence-based guideline. Pract Radiat Oncol 2012; 2(3): 210-25.
[65]
Yamamoto M, Kawabe T, Sato Y, et al. A case-matched study of stereotactic radiosurgery for patients with multiple brain metastases: comparing treatment results for 1-4 vs. ≥ 5 tumors: Clinical article. J Neurosurg 2013; 118(6): 1258-68.
[66]
Yamamoto M, Serizawa T, Shuto T, et al. Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): A multi-institutional prospective observational study. Lancet Oncol 2014; 15(4): 387-95.
[67]
Chang EL, Wefel JS, Hess KR, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: A randomised controlled trial. Lancet Oncol 2009; 10(11): 1037-44.
[68]
Cole AM, Scherwath A, Ernst G, et al. Self-reported cognitive outcomes in patients with brain metastases before and after radiation therapy. Int J Radiat Oncol Biol Phys 2013; 87(4): 705-12.
[69]
Soffietti R, Kocher M, Abacioglu UM, et al. A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: Quality-of-life results. J Clin Oncol 2013; 31(1): 65-72.
[70]
Aoyama H, Shirato H, Tago M, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs. stereotactic radiosurgery alone for treatment of brain metastases: A randomized controlled trial. JAMA 2006; 295(21): 2483-91.
[71]
Kocher M, Soffietti R, Abacioglu U, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: Results of the EORTC 22952-26001 study. J Clin Oncol 2011; 29(2): 134-41.
[72]
Sahgal A, Aoyama H, Kocher M, et al. Phase 3 trials of stereotactic radiosurgery with or without whole-brain radiation therapy for 1 to 4 brain metastases: Individual patient data meta-analysis. Int J Radiat Oncol Biol Phys 2015; 91(4): 710-7.
[73]
Arvold ND, Lee EQ, Mehta MP, et al. Updates in the management of brain metastases. Neuro-oncol 2016; 18(8): 1043-65.
[74]
Vecil GG, Suki D, Maldaun MV, Lang FF, Sawaya R. Resection of brain metastases previously treated with stereotactic radiosurgery. J Neurosurg 2005; 102(2): 209-15.
[75]
Patel SH, Robbins JR, Gore EM, et al. ACR appropriateness criteria® follow-up and retreatment of brain metastases. Am J Clin Oncol 2012; 35(3): 302-6.
[76]
Mulvenna P, Nankivell M, Barton R, et al. Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial. Lancet 2016; 388(10055): 2004-14.
[77]
Regine WF, Scott C, Murray K, Curran W. Neurocognitive outcome in brain metastases patients treated with accelerated-fractionation vs. accelerated-hyperfractionated radiotherapy: An analysis from Radiation Therapy Oncology Group Study 91-04. Int J Radiat Oncol Biol Phys 2001; 51(3): 711-7.
[78]
Li J, Bentzen SM, Renschler M, Mehta M. Regression after whole-brain radiation therapy for brain metastases correlates with survival and improved neurocognitive function. J Clin Oncol 2007; 25(10): 1260-6.
[79]
Brown PD, Pugh S, Laack NN, et al. Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: A randomized, double-blind, placebo-controlled trial. Neuro-oncol 2013; 15(10): 1429-37.
[80]
Rapp SR, Case LD, Peiffer A, et al. Donepezil for irradiated brain tumor survivors: A phase III randomized placebo-controlled clinical trial. J Clin Oncol 2015; 33(15): 1653-9.
[81]
Hochberg FH, Pruitt A. Assumptions in the radiotherapy of glioblastoma. Neurology 1980; 30(9): 907-11.
[82]
Matsukado Y, MacCarty CS, Kernohan JW. The growth of glioblastoma multiforme (astrocytomas, grades 3 and 4) in neurosurgical practice. J Neurosurg 1961; 18(5): 636-44.
[83]
Brandes AA, Tosoni A, Franceschi E, et al. Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: Correlation With MGMT promoter methylation status. J Clin Oncol 2009; 27(8): 1275-9.
[84]
Badiyan SN, Markovina S, Simpson JR, et al. Radiation therapy dose escalation for glioblastoma multiforme in the era of temozolomide. Int J Radiat Oncol Biol Phys 2014; 90(4): 877-85.
[85]
Iuchi T, Hatano K, Kodama T, et al. Phase 2 trial of hypofractionated high-dose intensity modulated radiation therapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastoma. Int J Radiat Oncol Biol Phys 2014; 88(4): 793-800.
[86]
Fitzek MM, Thornton AF, Rabinov JD, et al. Accelerated fractionated proton/photon irradiation to 90 cobalt gray equivalent for glioblastoma multiforme: Results of a phase II prospective trial. J Neurosurg 1999; 91(2): 251-60.
[87]
van der Heide UA, Houweling AC, Groenendaal G, Beets-Tan RG, Lambin P. Functional MRI for radiotherapy dose painting. Magn Reson Imaging 2012; 30(9): 1216-23.
[88]
Laprie A, Catalaa I, Cassol E, et al. Proton magnetic resonance spectroscopic imaging in newly diagnosed glioblastoma: Predictive value for the site of postradiotherapy relapse in a prospective longitudinal study. Int J Radiat Oncol Biol Phys 2008; 70(3): 773-81.
[89]
Ken S, Vieillevigne L, Franceries X, et al. Integration method of 3D MR spectroscopy into treatment planning system for glioblastoma IMRT dose painting with integrated simultaneous boost. Radiat Oncol 2013; 8: 1.
[90]
Laser BS, Merchant TE, Indelicato DJ, Hua CH, Shulkin BL, Snyder SE. Evaluation of children with craniopharyngioma using carbon-11 methionine PET prior to proton therapy. Neuro-oncol 2013; 15(4): 506-10.
[91]
Tsien CI, Brown D, Normolle D, et al. Concurrent temozolomide and dose-escalated intensity-modulated radiation therapy in newly diagnosed glioblastoma. Clin Cancer Res 2012; 18(1): 273-9.
[92]
Madani I, Lomax AJ, Albertini F, Trnková P, Weber DC. Dose-painting intensity-modulated proton therapy for intermediate- and high-risk meningioma. Radiat Oncol 2015; 10: 72.
[93]
Choi C, Ganji SK, DeBerardinis RJ, et al. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat Med 2012; 18(4): 624-9.
[94]
Abedalthagafi M, Bi WL, Aizer AA, et al. Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma. Neuro-oncol 2016; 18(5): 649-55.
[95]
Kieran MW. Targeting BRAF in pediatric brain tumors. Am Soc Clin Oncol Educ Book 2014; 2014: e436-40.
[96]
Xu LW, Chow KK, Lim M, Li G. Current vaccine trials in glioblastoma: A review. J Immunol Res 2014; 2014 796856
[97]
Chow KK, Hara W, Lim M, Li G. Combining immunotherapy with radiation for the treatment of glioblastoma. J Neurooncol 2015; 123(3): 459-64.
[98]
Newcomb EW, Demaria S, Lukyanov Y, et al. The combination of ionizing radiation and peripheral vaccination produces long-term survival of mice bearing established invasive GL261 gliomas. Clin Cancer Res 2006; 12(15): 4730-7.
[99]
Sampson JH, Heimberger AB, Archer GE, et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 2010; 28(31): 4722-9.
[100]
Shao H, Chung J, Lee K, et al. Chip-based analysis of exosomal mRNA mediating drug resistance in glioblastoma. Nat Commun 2015; 6: 6999.
[101]
Kazda T, Jancalek R, Pospisil P, et al. Why and how to spare the hippocampus during brain radiotherapy: the developing role of hippocampal avoidance in cranial radiotherapy. Radiat Oncol 2014; 9: 139.
[102]
Gondi V, Pugh SL, Tome WA, et al. Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): A phase II multi-institutional trial. J Clin Oncol 2014; 32(34): 3810-6.
[103]
Fisher BJ, Hu C, Macdonald DR, et al. Phase 2 study of temozolomide-based chemoradiation therapy for high-risk low-grade gliomas: Preliminary results of Radiation Therapy Oncology Group 0424. Int J Radiat Oncol Biol Phys 2015; 91(3): 497-504.
[104]
Rogers L, Zhang P, Vogelbaum M, et al. Intermediate-risk meningioma: Initial outcomes from NRG Oncology/RTOG-0539. Int J Radiat Oncol Biol Phys 2015; 93(3 suppl): S139-40.
[105]
Kaur G, Sayegh ET, Larson A, et al. Adjuvant radiotherapy for atypical and malignant meningiomas: A systematic review. Neuro-oncol 2014; 16(5): 628-36.
[106]
Murphy ES, Suh JH. Radiotherapy for vestibular schwannomas: A critical review. Int J Radiat Oncol Biol Phys 2011; 79(4): 985-97.
[107]
Brennan C, Yang TJ, Hilden P, et al. A phase 2 trial of stereotactic radiosurgery boost after surgical resection for brain metastases. Int J Radiat Oncol Biol Phys 2014; 88(1): 130-6.
[108]
Gaspar L, Scott C, Rotman M, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997; 37(4): 745-51.
[109]
Powell C, Guerrero D, Sardell S, et al. Somnolence syndrome in patients receiving radical radiotherapy for primary brain tumours: A prospective study. Radiother Oncol 2011; 100(1): 131-6.
[110]
Maranzano E, De Angelis V, Pergolizzi S, et al. A prospective observational trial on emesis in radiotherapy: Analysis of 1020 patients recruited in 45 Italian radiation oncology centres. Radiother Oncol 2010; 94(1): 36-41.
[111]
Shakespeare TP, Dwyer M, Mukherjee R, Yeghiaian-Alvandi R, Gebski V. Estimating risks of radiotherapy complications as part of informed consent: The high degree of variability between radiation oncologists may be related to experience. Int J Radiat Oncol Biol Phys 2002; 54(3): 647-53.
[112]
Lawenda BD, Gagne HM, Gierga DP, et al. Permanent alopecia after cranial irradiation: Dose-response relationship. Int J Radiat Oncol Biol Phys 2004; 60(3): 879-87.
[113]
Jereczek-Fossa BA, Zarowski A, Milani F, Orecchia R. Radiotherapy-induced ear toxicity. Cancer Treat Rev 2003; 29(5): 417-30.
[114]
Taal W, Brandsma D, de Bruin HG, et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer 2008; 113(2): 405-10.
[115]
O’Brien BJ, Colen RR. Post-treatment imaging changes in primary brain tumors. Curr Oncol Rep 2014; 16(8): 397.
[116]
Armstrong C, Ruffer J, Corn B, DeVries K, Mollman J. Biphasic patterns of memory deficits following moderate-dose partial-brain irradiation: Neuropsychologic outcome and proposed mechanisms. J Clin Oncol 1995; 13(9): 2263-71.
[117]
Appelman-Dijkstra NM, Kokshoorn NE, Dekkers OM, et al. Pituitary dysfunction in adult patients after cranial radiotherapy: Systematic review and meta-analysis. J Clin Endocrinol Metab 2011; 96(8): 2330-40.
[118]
Aizer AA, Du R, Wen PY, Arvold ND. Radiotherapy and death from cerebrovascular disease in patients with primary brain tumors. J Neurooncol 2015; 124(2): 291-7.
[119]
van Kempen-Harteveld ML, Struikmans H, Kal HB, et al. Cataract after total body irradiation and bone marrow transplantation: Degree of visual impairment. Int J Radiat Oncol Biol Phys 2002; 52(5): 1375-80.
[120]
Mayo C, Martel MK, Marks LB, Flickinger J, Nam J, Kirkpatrick J. Radiation dose-volume effects of optic nerves and chiasm. Int J Radiat Oncol Biol Phys 2010; 76(3)(Suppl.): S28-35.
[121]
Parsons JT, Bova FJ, Fitzgerald CR, Mendenhall WM, Million RR. Radiation retinopathy after external-beam irradiation: Analysis of time-dose factors. Int J Radiat Oncol Biol Phys 1994; 30(4): 765-73.
[122]
Nakissa N, Rubin P, Strohl R, Keys H. Ocular and orbital complications following radiation therapy of paranasal sinus malignancies and review of literature. Cancer 1983; 51(6): 980-6.
[123]
Hua C, Bass JK, Khan R, Kun LE, Merchant TE. Hearing loss after radiotherapy for pediatric brain tumors: Effect of cochlear dose. Int J Radiat Oncol Biol Phys 2008; 72(3): 892-9.
[124]
Johannesen TB, Rasmussen K, Winther FØ, Halvorsen U, Lote K. Late radiation effects on hearing, vestibular function, and taste in brain tumor patients. Int J Radiat Oncol Biol Phys 2002; 53(1): 86-90.
[125]
Galloway TJ, Indelicato DJ, Amdur RJ, et al. Second tumors in pediatric patients treated with radiotherapy to the central nervous system. Am J Clin Oncol 2012; 35(3): 279-83.
[126]
Bowers DC, Liu Y, Leisenring W, et al. Late-occurring stroke among long-term survivors of childhood leukemia and brain tumors: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2006; 24(33): 5277-82.
Call for Papers in Thematic Issues
02 October, 2024
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
Related Journals
Anti-Cancer Agents in Medicinal Chemistry
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Current Bioactive Compounds
Current Cancer Drug Targets
Combinatorial Chemistry & High Throughput Screening
Current Diabetes Reviews
Current Drug Safety
Current Drug Targets
Current Drug Therapy
Current Drug Delivery
Related Books
Drug Addiction Mechanisms in the Brain
Software and Programming Tools in Pharmaceutical Research
Objective Pharmaceutics: A Comprehensive Compilation of Questions and Answers for Pharmaceutics Exam Prep
Medicinal Chemistry of Drugs Affecting Cardiovascular and Endocrine Systems
Frontiers in Clinical Drug Research - Anti-Cancer Agents
The Management of Metastatic Triple-Negative Breast Cancer: An Integrated and Expeditionary Approach
Advanced Pharmacy
Plant-derived Hepatoprotective Drugs
Cancer Genes
The Role of Chromenes in Drug Discovery and Development
Article Metrics
27